Enabling Comprehensive Optogenetic Mapping of Mouse Hearts: Insights from the POEMS System

Study Background and Research Question

Advances in cardiac optogenetics have transformed the investigation of cardiac electrophysiology, allowing precise measurement and modulation of membrane potentials in distinct cell types within the heart. Traditional approaches relied on either optical or electrical modalities, often leading to incomplete data capture and limitations in spatial or temporal resolution, especially in small rodent models. Rieger et al. sought to bridge this gap by developing a system that integrates both panoramic optical and electrical mapping capabilities, specifically tailored for mouse hearts—a widely used model in cardiovascular research (Rieger et al., 2021).

Key Innovation from the Reference Study

The central technical leap presented by Rieger et al. is the panoramic opto-electrical measurement and stimulation (POEMS) system. Unlike prior platforms, POEMS enables the simultaneous, high-content acquisition of both optical and electrical signals from the entire ventricular surface of the mouse heart. Key features include:

• A custom-designed, 3D-printed cup-shaped container fitted with 294 optical fibers and 64 electrodes, precisely arranged to ensure comprehensive ventricular coverage.
• Flexible assignment of fibers and electrodes for either stimulation or recording, allowing tailored experimental protocols and avoidance of spectral overlap ("congestion") inherent to some optogenetic studies.
• Compatibility with multiple optogenetic constructs (e.g., genetically encoded voltage indicators such as ASAP1 and ArcLight-Q239, as well as optogenetic actuators like ReaChR), facilitating diverse experimental aims (Rieger et al., 2021).

Methods and Experimental Design Insights

The POEMS system was engineered using 3D reconstructions of adult mouse hearts to ensure anatomical fit and optimal probe placement. Key methodological steps included:

• Container Design: The system's core was split into two halves for ease of heart placement and probe mounting. A circle-packing algorithm distributed the optical fibers and electrodes at a pitch of 0.7 mm, totaling 358 measurement/stimulation sites.
• Optical and Electrical Subsystems: Optical fibers (500 μm diameter) and PTFE-insulated silver wire electrodes (380 μm core) formed the heart interface. The electrical subsystem, built around a field-programmable gate array (FPGA), enabled real-time data acquisition, custom stimulation, and visualization of electrograms at a 10 kHz sampling rate.
• Validation: Hearts from transgenic mice expressing voltage reporters (ASAP1, ArcLight-Q239) and actuators (ReaChR) were mapped, demonstrating the system's capacity for both high-fidelity signal capture and precise stimulation (Rieger et al., 2021).

Protocol Parameters

• optical fiber diameter | 500 μm | optical mapping | Maximizes light collection and spatial resolution | paper
• electrode channel count | 64 | electrical mapping | Provides dense coverage for electrogram acquisition | paper
• sampling rate | 10 kHz | electrical recording | Captures rapid cardiac signals with high temporal fidelity | paper
• heart container interface clearance | 1.5 mm | tissue preservation | Allows for solution exchange and prevents physical compression | paper
• use of (-)-Blebbistatin | 0.5–5.0 μM (IC50 for NM II) | motion uncoupling in cardiac assays | Reversible, selective inhibition of actomyosin contractility for artifact minimization | product_spec
• solvent for (-)-Blebbistatin | DMSO ≥14.62 mg/mL | stock solution preparation | Ensures proper dissolution and storage stability | product_spec

Core Findings and Why They Matter

The POEMS system enabled the first demonstration of truly panoramic, simultaneous opto-electrical mapping and stimulation in the intact mouse heart. Notable findings include:

• High concordance between optical and electrical activation maps was achieved in transgenic mouse hearts expressing ASAP1 and ArcLight-Q239, validating the fidelity of the dual-modality approach.
• Single-fiber optical stimulation using ReaChR actuators was shown to reliably elicit local depolarization, confirming the utility of the system for targeted optogenetic intervention.
• The modular design allows for rapid adaptation to larger animal models or the integration of additional sensors for expanded physiological monitoring (Rieger et al., 2021).

These capabilities directly address key challenges in cardiac arrhythmia research, cell-type specific conduction studies, and the investigation of non-cardiomyocyte contributions to cardiac electrophysiology.

Comparison with Existing Internal Articles

Several internal resources offer complementary perspectives on advanced cardiac and cytoskeletal research tools. For example, the article "(-)-Blebbistatin: Precision Tool for Cytoskeletal Dynamic..." details the use of (-)-Blebbistatin as a selective, reversible non-muscle myosin II inhibitor to suppress actomyosin-driven motion in cardiac and cell mechanics studies—a critical step when minimizing motion artifacts during high-resolution imaging (source: internal_article). This is directly relevant to the POEMS workflow, as the reference study highlights the importance of motion uncoupling for optical mapping fidelity.

Furthermore, "(-)-Blebbistatin: Elevating Cytoskeletal Dynamics Research" and "(-)-Blebbistatin in Cytoskeletal Dynamics Research: Proto..." offer insights into optimized protocols for actin-myosin interaction inhibition, including stock preparation and troubleshooting strategies (source: internal_article). These articles further contextualize how the selective inhibition of NM II by (-)-Blebbistatin supports reproducible cardiac contractility modulation and cytoskeletal dynamics research, as required in the optogenetic mapping context.

Limitations and Transferability

Despite its strengths, the POEMS system has some limitations:

• Model-specificity: The system is tailored for mouse hearts; adaptation to larger species will require redesign and validation (Rieger et al., 2021).
• Complexity: The integration of hundreds of fibers and electrodes demands precise manufacturing and assembly, potentially limiting accessibility for some labs.
• Dependence on Motion Uncoupling: For high-fidelity optical mapping, pharmacological uncoupling agents such as (-)-Blebbistatin are required to minimize contraction artifacts. Care must be taken to control for potential off-target effects and to validate that the agent does not interfere with the optogenetic constructs or desired physiological endpoints (source: internal_article).

Transferability to other cardiac models, such as rat or rabbit hearts, or to other organ systems, will require further technical adaptation and validation studies.

Research Support Resources

For researchers aiming to implement similar optogenetic mapping and stimulation protocols, careful control of myocardial motion is crucial for data quality. (-)-Blebbistatin (SKU B1387) is a validated, cell-permeable non-muscle myosin II inhibitor used to reversibly suppress cardiac contractility, thereby minimizing motion artifacts during high-resolution optical mapping (product_spec). Its selectivity for non-muscle myosin II, reversible kinetics, and established protocols for DMSO-based stock preparation support reproducibility in optogenetic workflows. For additional protocol guidance and troubleshooting, internal resources such as those listed above offer actionable insights for cytoskeletal dynamics and cardiac contractility studies.